Nanomedicines | CHOP Research Institute

Chorny Laboratory

The laboratory led by Michael Chorny, PhD, designs delivery systems for drugs and biotherapeutics, focusing on vascular proliferative diseases and high-risk malignancies. Biodegradable nanoparticles and prodrugs are optimized to enhance and extend therapeutic activity, and minimize adverse effects.

Levy Laboratory

Research in the Levy Lab centers on the pathophysiology of biomaterials used in medicine, basic mechanisms and novel therapies for heart valve disease, arterial angioplasty, local drug delivery, and nanomedicine.

Brodeur Laboratory

Research in the Brodeur Lab focuses on two main areas: nanoparticle drug delivery and cancer predisposition. Nanomedicines allow the delivery of much more drug to the tumor and much less to the patient.

Garrett M. Brodeur, MD

Dr. Broedur’s research interests focus on nanoparticle drug delivery and cancer predisposition. He is also interested in identifying novel cancer predisposition genes, and developing enhanced surveillance techniques to identify cancer early in predisposed individuals with the hope of improving outcome and reducing side effects.

E-mail:

brodeur [at] chop.edu

Robert J. Levy, MD

Dr. Levy is the director of Cardiology Research, and also serves as program director of the Cardiology National Heart, Lung, and Blood Institute (NHLBI) Research Training Grant. His research interests are the pathophysiology of biomaterials used in medicine, basic mechanisms and novel therapies for heart valve disease, arterial angioplasty, local drug delivery, and nanomedicine. He also has experience over three decades in medical device development.

E-mail:

levyr [at] chop.edu

Four Investigators Awarded Childhood Cancer Research Grants From St. Baldrick's

Published on

Oct 18, 2018

in Cornerstone Blog

New St. Baldrick's research grant awards support our investigators' exploration of new approaches to pediatric cancer.